research use only

BMS202 PD-1/PD-L1 inhibitor

Name: BMS202
Brand: Selleck Chemicals
SKU: S7912
Availability: InStock
Rating: 5 (26 reviews)

Cat.No.S7912

BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.

Chemical Structure

Molecular Weight: 419.52

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.87%

99.87

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF STING AhR IL Receptor NADPH-oxidase Complement System IRAK β-lactamase IDO/TDO PGES FKBP LTR
Related Products	BMS-1 PD-1/PD-L1 Inhibitor 3 BMS-1166 AUNP-12 Anti-mouse PD-L1 (B7-H1)-InVivo SR 0987 Spartalizumab (anti-PD-1) GS-4224 PD-L2 Antibody [C11K4] Serplulimab (Anti-PDCD1 / PD-1 / CD279) Toripalimab (Anti-PDCD1 / PD-1 / CD279) Dostarlimab (Anti-PDCD1 / PD-1 / CD279) Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo Anti-human PD-L1 (B7-H1)-InVivo PD-L1 Antibody [G4H2] CA-170 (AUPM-170) Finotonlimab (Anti-PDCD1 / PD-1 / CD279) Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) VISTA Antibody [G23H7] Geptanolimab (Anti-PDCD1 / PD-1 / CD279) PD-L2 Antibody [K17B13] Iparomlimab (Anti-PDCD1 / PD-1 / CD279) Anti-mouse PD-1 (CD279)-InVivo Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) PD-1 (Intracellular Domain) Antibody [G6H24] Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo Cadonilimab (Anti-PD-1 & CTLA-4) Pm8002 (Anti-PD-L1 & VEGF) Opucolimab (Anti-B7-H1 / PD-L1 / CD274)

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Activity Description	PMID
BL21(DE3)	Function assay	Binding affinity to [15N-Tyr]-labeled human PD-L1 (18 to 134 residues) expressed in Escherichia coli BL21(DE3) by 1H-15N 2D HMQC NMR spectroscopic analysis.	28613862
BL21(DE3)	Function assay	Binding affinity to [15N-Val]-labeled human PD-L1 (18 to 134 residues) expressed in Escherichia coli BL21(DE3) by 1H-15N 2D HMQC NMR spectroscopic analysis.	28613862
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	419.52	Formula	C₂₅H₂₉N₃O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1675203-84-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	PD-1/PD-L1 inhibitor 2			Smiles	CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (197.84 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 83 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 5%Tween80 2 90%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.100mg/ml (2.62mM)	Taking the 1 mL working solution as an example, add 50 μL of 22 mg/ml clarified DMSO stock solution to 50 μL of Tween80, mix evenly to clarify; then continue to add 900 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (4.77mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	PD-1/PD-L1 interaction ^[2] (Cell-free assay) 0.018 μM
In vitro	BMS-202 inhibits PD-1/PD-L1 binding in SCC-3 and Jurkat cells with IC50 of 15 μM and 10 μM, respectively.
In vivo	BMS-202 treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice.
References	[1] https://patents.google.com/patent/WO2015034820A1 [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058683/ [3] https://pubmed.ncbi.nlm.nih.gov/31839668/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to know the difference of S8158, S7912, S7911, and the reason of why the IC50 is different for it.

Answer:
It is a small-molecule inhibitor and one of three different PD-L1/PD-L1 inhibitors. These three compounds have different structures, characteristics, and probably function through different mechanisms. And this is why the IC50s are different. Inhibitor 1 and 2 are also small-molecule inhibitors while inhibitor 3 is a macrocyclic inhibitor.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):